I've read these over the past few years previously being a shareholder of Clinuvel who are trialling their drug for AIS. The economic impact is staggering not to mention the disruption and loss of quality of life for patients and families. Which is why I hold the view that even a small but discernible improvement in stroke patients via ARG-007 will have a good chance of being approved. I personally believe that the drug will offer more than a just a small improvement, but we have a long way to go.
Economic cost of stroke 2024 report, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
0.020(2.70%) |
Mkt cap ! $97.35M | |||
| Open | High | Low | Value | Volume |
| 73.5¢ | 76.0¢ | 72.3¢ | $96.97K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 73.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.40pm 27/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |